Sagimet Biosciences Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Sagimet Biosciences Inc. (SGMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $200.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2025-11-13
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $0.00.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-06-30 was $0.00.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-03-31 was $100.00K.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $100.00K, a 0.00% change from fiscal 2023.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $100.00K, a 4900.00% increase from fiscal 2022.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $2.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-09-30 | $200.00K 10-Q · filed 2025-11-13 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 derived: sum of 3 quarters · filed 2025-11-13 | $100.00K 10-K · filed 2025-03-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $100.00K 10-Q · filed 2025-11-13 | $100.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $100.00K 10-Q · filed 2025-08-13 | $100.00K derived: sum of 3 quarters · filed 2025-08-13 | $200.00K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-08 | $100.00K derived: sum of 2 quarters · filed 2025-05-08 | $200.00K derived: sum of 3 quarters · filed 2025-05-08 | $200.00K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $100.00K derived: sum of 2 quarters · filed 2025-03-12 | $100.00K derived: sum of 3 quarters · filed 2025-03-12 | $100.00K 10-K · filed 2025-03-12 | $88.00K 10-K · filed 2024-03-25 |
| 2023-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $100.00K derived: sum of 2 quarters · filed 2024-11-14 | $100.00K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | $2.00K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |